# TAVALISSE (fostamatinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/fostamatinib

> TAVALISSE (fostamatinib), sponsored by RIGEL PHARMACEUTICALS INC (RIGL): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TAVALISSE (fostamatinib) |
| Codes |  |
| Sponsor | RIGEL PHARMACEUTICALS INC (RIGL) https://sec-api.dev/companies/rigl/catalysts |
| Indications |  |
| Modality | small_molecule |
| FDA designations | orphan |

## Timeline

### Jun 2022: topline data readout

- Status: completed, missed. Date confidence: month.
- First seen 2025-03-04, last confirmed 2025-11-04.
- SEC Form 10-Q (accession 0001104659-25-106268): "In June 2022, we announced top-line efficacy and safety data results of the trial, and the results did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population." https://www.sec.gov/Archives/edgar/data/1034842/000110465925106268/rigl-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010281): "In June 2022, we announced top-line efficacy and safety data results of the trial, and the results did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population." https://www.sec.gov/Archives/edgar/data/1034842/000155837025010281/rigl-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006493): "In June 2022, we announced top-line efficacy and safety data results of the trial, and the results did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population." https://www.sec.gov/Archives/edgar/data/1034842/000155837025006493/rigl-20250331x10q.htm
- SEC Form 10-Q (accession 0001104659-25-106268): "For example, in June 2022, we announced that the top-line results from our Phase 3 trial in wAIHA did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population." https://www.sec.gov/Archives/edgar/data/1034842/000110465925106268/rigl-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010281): "For example, in June 2022, we announced that the top-line results from our Phase 3 trial in wAIHA did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population." https://www.sec.gov/Archives/edgar/data/1034842/000155837025010281/rigl-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006493): "For example, in June 2022, we announced that the top-line results from our Phase 3 trial in wAIHA did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population." https://www.sec.gov/Archives/edgar/data/1034842/000155837025006493/rigl-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-002169): "For example, in June 2022, we announced that the top-line results from our Phase 3 trial in wAIHA did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population." https://www.sec.gov/Archives/edgar/data/1034842/000155837025002169/rigl-20241231x10k.htm

### Nov 2022: topline data readout

- Status: completed, missed. Date confidence: month.
- First seen 2025-03-04, last confirmed 2025-11-04.
- SEC Form 10-Q (accession 0001104659-25-106268): "We previously announced in November 2022 the top-line results did not meet statistical significance in the primary efficacy endpoint." https://www.sec.gov/Archives/edgar/data/1034842/000110465925106268/rigl-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010281): "We previously announced in November 2022 the top-line results did not meet statistical significance in the primary efficacy endpoint." https://www.sec.gov/Archives/edgar/data/1034842/000155837025010281/rigl-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006493): "We previously announced in November 2022 the top-line results did not meet statistical significance in the primary efficacy endpoint." https://www.sec.gov/Archives/edgar/data/1034842/000155837025006493/rigl-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-002169): "We previously announced in November 2022 the top-line results did not meet statistical significance in the primary efficacy endpoint." https://www.sec.gov/Archives/edgar/data/1034842/000155837025002169/rigl-20241231x10k.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/fostamatinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TAVALISSE (fostamatinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/fostamatinib

```bibtex
@misc{secapidev_pdufa_fostamatinib_20261116,
  title        = {TAVALISSE (fostamatinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/fostamatinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_fostamatinib_20261116","title":"TAVALISSE (fostamatinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/fostamatinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
